Evidence map›Paper›PMID 42146863›Full record

ArticleSovremennye tekhnologii v meditsine2026

Functional Suitability Evaluation of Radioimmunoconjugates of Nanobodies against PD-L1 and HER2/neu for Tumor Theranostics.

K O Avrov, S V Shatik, O A Shashkova, A A Pinevich, L A Terekhina, I V Gryazeva, V V Zaitsev, M A Berlina, A A Stanzhevsky, M P Samoylovich

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Sovremennye tekhnologii v meditsine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

K O AvrovPhD, Senior Researcher, Laboratory of Hybridoma Technology; Russian Scientific Center of Radiology and Surgical Technologies named after Academician A.M. Granov, Ministry of Health of the Russian Federation, 70 Leningradskaya St., Saint Petersburg, Pesochny Settlement, 197758, Russia.
S V ShatikPhD, Leading Researcher, Laboratory of Radiopharmaceutical Technologies; Russian Scientific Center of Radiology and Surgical Technologies named after Academician A.M. Granov, Ministry of Health of the Russian Federation, 70 Leningradskaya St., Saint Petersburg, Pesochny Settlement, 197758, Russia.
O A ShashkovaPhD, Senior Researcher, Laboratory of Hybridoma Technology; Russian Scientific Center of Radiology and Surgical Technologies named after Academician A.M. Granov, Ministry of Health of the Russian Federation, 70 Leningradskaya St., Saint Petersburg, Pesochny Settlement, 197758, Russia.
A A PinevichPhD, Senior Researcher, Laboratory of Hybridoma Technology; Russian Scientific Center of Radiology and Surgical Technologies named after Academician A.M. Granov, Ministry of Health of the Russian Federation, 70 Leningradskaya St., Saint Petersburg, Pesochny Settlement, 197758, Russia.
L A TerekhinaResearcher, Laboratory of Hybridoma Technology; Russian Scientific Center of Radiology and Surgical Technologies named after Academician A.M. Granov, Ministry of Health of the Russian Federation, 70 Leningradskaya St., Saint Petersburg, Pesochny Settlement, 197758, Russia.
I V GryazevaPhD, Senior Researcher, Laboratory of Hybridoma Technology; Russian Scientific Center of Radiology and Surgical Technologies named after Academician A.M. Granov, Ministry of Health of the Russian Federation, 70 Leningradskaya St., Saint Petersburg, Pesochny Settlement, 197758, Russia.
V V ZaitsevLeading Researcher, Laboratory of Radiopharmaceutical Technologies; Russian Scientific Center of Radiology and Surgical Technologies named after Academician A.M. Granov, Ministry of Health of the Russian Federation, 70 Leningradskaya St., Saint Petersburg, Pesochny Settlement, 197758, Russia.
M A BerlinaResearch Assistant, Laboratory of Hybridoma Technology; Russian Scientific Center of Radiology and Surgical Technologies named after Academician A.M. Granov, Ministry of Health of the Russian Federation, 70 Leningradskaya St., Saint Petersburg, Pesochny Settlement, 197758, Russia.
A A StanzhevskyMD, DSc, Deputy Director for Research; Russian Scientific Center of Radiology and Surgical Technologies named after Academician A.M. Granov, Ministry of Health of the Russian Federation, 70 Leningradskaya St., Saint Petersburg, Pesochny Settlement, 197758, Russia.
M P SamoylovichDSc, Chief Researcher, Laboratory of Hybridoma Technology; Russian Scientific Center of Radiology and Surgical Technologies named after Academician A.M. Granov, Ministry of Health of the Russian Federation, 70 Leningradskaya St., Saint Petersburg, Pesochny Settlement, 197758, Russia; Chief Researcher, Department of Cytology and Histology, Faculty of Biology; Saint Petersburg State University, Universitetskaya Embankment, 7/9 Saint Petersburg, 199034, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Materials and Methods: The nanobodies to human biomarkers PD-L1 and HER2/neu were conjugated with radionuclides Conclusion: The findings indicated the functional suitability of the pairs of RIC nanobodies with

Indexed as

B7-H1 AntigenErb-b2 Receptor Tyrosine KinasesImmunoconjugatesSingle-Domain AntibodiesTheranostic NanomedicineAnimalsCell Line, TumorFemaleHumansLutetiumMiceRadioisotopesTissue DistributionB7-H1 AntigenCD274 protein, humanERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesImmunoconjugatesLutetiumRadioisotopesSingle-Domain AntibodiesHER2/neunanobodiesPD-L1radioimmunoconjugatesradionuclidestheranostics

Identifiers

PMID42146863
PMCPMC13178089

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.